Abstract 107P
Background
The highest prevalence of MSI is observed in colorectal (CRC), endometrial, and gastric cancers. Lately, MSI has expanded its clinical utility as predictive biomarker to immunotherapy (IO). IHC and/or PCR are the gold standard methods for MSI detection, though NGS arises as a promising approach to expand the spectrum of malignancies in which we can detect dMMR or MSI-H.
Methods
We performed a multicentric retrospective study of adult pt with advanced solid malignancies evaluated through a coordinated NGS MPP at three different Catalan Institute of Oncology centres in Catalonia, Spain. Tumors were profiled with NGS Oncomine Comprehensive Assay v3 (OCAv3) or with Illumina TruSight Oncology 500 (TSO500) assay. Both tests detected mutations (mut) in MMR genes, but TSO500 also included MSI-H percentage repeats. Molecular results were weekly reviewed in dedicated molecular tumor boards (MTB) and correlated with IHC/PCR. The aim of the study was to describe the characteristics of dMMR/MSI-H pt and their clinical benefit (ClinBen) if treated with IO, defined as response or stable disease >4 months.
Results
From Mar’21 to Jul’23, 1514 pt were NGS analysed and 23 cases were considered dMMR/MSI-H. Histologies were CRC (12), NSCLC (6), endometrial (1) breast (1), carcinoma of unknown origin (CUD; 1), adrenal carcinoma (AC; 1) and glioma (1). Mut in MMR genes were detected in 19 tumors (14/808 OCAv3 and 5/706 TSO500): MLH1mut (9), MSH6mut (5), MSH2mut (5) and PMS2mut (2). Two CRC pt harbored co-existing MSH2/MSH6mut. Before the NGS results, only 10 MMR-mutated pt were previously identified as MSI-H by IHC/PCR and all of them had tumors with high prevalence dMMR/MSI-H (9 CRC, 1 endometrial). Lynch sd. was established in 6 of these cases. Noteworthy, TSO500 detected 9 MSI-H tumors of whom 4 had no underlying MMRmut. ClinBen was achieved in 6 out of 9 pt treated with IO.
Conclusions
Our results show that NGS MPP and MTB help to molecularly characterize multiple tumor types, widening the detection of dMMR/MSI cases. Uncommon histologies, such as CUD, AC or gliomas, can therapeutically benefit from this approach.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.A. Bergamino: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Funding, Travel funding for congress: Novartis; Financial Interests, Personal, Funding, Travel funding for congresses: Eisai.J. Martin-Liberal: Financial Interests, Personal, Invited Speaker: Astellas, Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Novartis, Pierre Fabre, Roche, Sanofi, Highlight Therapeutics; Financial Interests, Personal, Other, Travel grant: Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Ipsen. C. Lazaro: Financial Interests, Personal, Advisory Board, Advisory boards on BRCA and HRD testing: AstraZeneca; Financial Interests, Personal, Advisory Board, IVDR advisory group: Illumina; Financial Interests, Institutional, Funding: AstraZeneca. C. Hierro: Financial Interests, Personal, Invited Speaker: MSD, Lilly; Financial Interests, Personal, Research Grant, Principal Investigator of Merck Research Grant in Personalized Medicine 2020: Merck; Non-Financial Interests, Personal, Principal Investigator, Clinical Trial: BMS, Zymeworks, ALX Oncology, AstraZeneca; Other, Personal, Other, Travel fees: BMS, Amgen, Roche, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract